Phase I/II TRIDENT-1 Update
TRIDENT-1 Update: Phase I/II Study of Repotrectinib in Patients With ROS1 Fusion–Positive Advanced NSCLC

Released: September 15, 2023

Activity

Progress
1
Course Completed